Role of Zinc in Bone Metabolism and Preventive Effect on Bone Disorder

この論文にアクセスする

この論文をさがす

著者

抄録

Zinc is essential for the growth of the human and animals. Bone growth retardation is a common finding in various conditions associated with zinc deficiency, suggesting a physiologic role of zinc in the growth and mineralization of bone tissues. Bone zinc content is decreased by development with aging, skeletal unloading, and postmenopausal conditions. Zinc deficiency may play a pathophysiologic role in the deteriodation of bone metabolism. Zinc has been demonstrated to have a stimulatory effect on osteoblastic bone formation and mineralization; the metal directly activates aminoacyl-tRNA synthetase, a rate-limiting enzyme at translational process of protein synthesis, in osteoblastic cells, and it stimulates cellular protein synthesis. Zinc has been shown to stimulate gene expression of the transcription facter Runx2 that is related to differentiation into osteoblastic cells. Moreover, zinc inhibits osteoclastic bone resorption due to inhibiting osteoclast-like cell formation from bone marrow cells and stimulating apoptotic cell death of mature osteoclasts. Zinc has a suppressive effect on the receptor activator of nuclear factor(NF)-κB ligand(RANKL)-induced osteoclastogenesis, indicating that the metal inhibits RANKL signaling in pre-osteoclasts. Zinc may act on the process of bone resorbing factors-induced protein kinase C activation, which is involved in Ca<sup>2+</sup> signaling in osteoclastic cells. Zinc plays a role in the preservation of bone mass. β-Alanyl-L-histidinato zinc(AHZ)is a zinc compound, in which zinc is chelated to β-alanyl-L-histidine. The stimulatory effect of AHZ on bone formation was more intensive than that of zinc sulfate. Also, zinc acexamate has a potent- anabolic effect on bone metabolism. The effect of AHZ or zinc acexamate on bone formation is equal in comparison with the effect of various bone-regulating hormones and other factors. The oral administration of AHZ or zinc acexamate has a fine restorative effect on bone loss with various pathophysiologic conditions(including aging, skeletal unloading, aluminium bone toxicity, calcium- and vitamin D-deficiency, adjuvant arthritis, estrogen deficiency, diabetes, and fracture healing). Zinc compounds may be designed as new drugs in the therapy of osteoporosis.

収録刊行物

  • Biomedical research on trace elements  

    Biomedical research on trace elements 18(4), 346-366, 2007-12-31 

    Japan Society for Biomedical Research on Trace Elements

参考文献:  111件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

被引用文献:  1件

被引用文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10021097590
  • NII書誌ID(NCID)
    AN10423256
  • 本文言語コード
    ENG
  • 資料種別
    REV
  • ISSN
    0916717X
  • NDL 記事登録ID
    9412396
  • NDL 雑誌分類
    ZS8(科学技術--医学--解剖学・生理学・生化学)
  • NDL 請求記号
    Z19-3255
  • データ提供元
    CJP書誌  CJP引用  NDL  J-STAGE 
ページトップへ